Neogen (NASDAQ:NEOG) Corporation reported its first-quarter fiscal 2025 financial results, revealing a surprising earnings per share (EPS) beat against analyst forecasts. Despite the positive earnings news, the company's stock saw a decline in premarket trading. Neogen's revenue and adjusted net income showed resilience, yet challenges in market dynamics and operational transitions were evident.
Key Takeaways
- Neogen's EPS of $0.11 surpassed the forecast of -$0.01.
- Revenue reached $231.3 million, exceeding the $226.19 million forecast.
- Premarket trading saw Neogen's stock price drop by 2.83%.
- The company maintains its previous fiscal year guidance.
- Strong international presence and new product developments continue.
Company Performance
Neogen Corporation demonstrated robust performance in Q1 2025, with an EPS of $0.11, significantly surpassing expectations. The company reported a revenue of $231.3 million, reflecting a positive variance from the forecasted $226.19 million. Neogen's ability to exceed financial expectations highlights its resilience amidst ongoing market challenges, including supply chain disruptions and competitive pressures.
Financial Highlights
- Revenue: $231.3 million, up from the forecast of $226.19 million.
- Earnings per share: $0.11, compared to a forecast of -$0.01.
- Gross margin: 48.4%, a decrease of 2.60 basis points year-over-year.
- Adjusted net income: $14 million, or $0.07 per share.
- Gross debt: $900 million; total cash position: $120 million.
Earnings vs. Forecast
Neogen's actual EPS of $0.11 came as a positive surprise against the forecast of -$0.01, marking a significant beat. The revenue also exceeded expectations, coming in at $231.3 million versus the anticipated $226.19 million. This performance marks a notable improvement compared to previous quarters, where the company faced challenges in meeting expectations.
Market Reaction
Despite the earnings beat, Neogen's stock experienced a 2.83% decline in premarket trading, with a price drop to $12.70. This movement contrasts with the broader market trends, which have been relatively stable. The stock's decline may reflect investor concerns over operational challenges and future growth prospects.
Outlook & Guidance
Neogen is maintaining its previous fiscal year guidance, anticipating a more weighted performance in the second half of the year. The company expects margin improvements in upcoming quarters and aims for positive free cash flow by year-end. Neogen projects net leverage to be around 3x by year-end, indicating a focus on financial stability.
Executive Commentary
CEO John Adent emphasized Neogen's leadership in the food safety market, stating, "We are the established leader in this market and look forward to continuing to build on that position to drive sustainable long-term growth." He also highlighted the company's commitment to preventing foodborne illnesses: "Our job is to make sure [foodborne illness] doesn't happen."
Q&A
During the earnings call, analysts inquired about Neogen's customer share loss of approximately $8 million in Q1. The company stressed its efforts to ensure consistent supply and rebuild customer trust. Additionally, Neogen is focusing on international market expansion and evaluating its product portfolio for potential consolidation.
Risks and Challenges
- Supply chain issues: Previous disruptions have impacted market share.
- Market saturation: Increased competition in the food safety sector.
- Macroeconomic pressures: Global economic uncertainty could affect growth.
- Operational transitions: Leadership changes may impact strategic continuity.
- Regulatory changes: Adapting to evolving global food safety regulations.
Full transcript - Neogen Corporation (NEOG) Q1 2025:
Conference Operator: Good morning, ladies and gentlemen, and welcome to the Neogen Corporation First Quarter 2025 Earnings Call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded on Tuesday, October 10, 2024. I would now like to turn the conference over to Bill Waelke, VP, Investor Relations and Treasury.
Please go ahead.
Bill Waelke, VP, Investor Relations and Treasury, Neogen Corporation: Thank you for joining us this morning for the discussion of the Q1 of our 2025 fiscal year. I'll briefly cover the non GAAP and forward looking language before passing the call over to our CEO, John Adent, who will be followed by our CFO, Dave Namura. Before the market opened today, we published our Q1 results as well as a presentation with both documents available in the Investor Relations section of our website. On our call this morning, we will refer to certain non GAAP financial measures that we believe are useful in evaluating our performance. Reconciliations of historical non GAAP financial measures are included in our earnings release and the presentation, Slide 2 of which provides a reminder that our remarks will include forward looking statements within the meaning of the Private Securities Litigation Reform Act.
These forward looking statements are subject to risks that could cause actual results to be materially different from those expressed in or implied by such forward looking statements. These risks include, among others, matters that we have described in our most recent annual report on Form 10 ks and in other filings we make with the SEC. We disclaim any obligation to update these forward looking statements. With that, I'll turn things over to John.
John Adent, CEO, Neogen Corporation: Thanks, Bill. Good morning, everyone, and welcome to the earnings call for the Q1 of our 2025 fiscal year. At the beginning of September, we crossed the 2 year anniversary of the closing of the 3 ms Food Safety transaction, which solidified our position as the largest player with the broadest product portfolio and geographic reach in an attractive and important end market. That transaction strengthened our company in the food safety end market, where we generate approximately 2 thirds of our revenue from products and solutions that help protect the food supply. We provide an important and relatively inexpensive line of defense in the rapid detection of contaminants in the production and distribution of food and beverages.
We believe the food safety market has a number of secular tailwinds. One of these tailwinds involves the expected increase in various food testing regulatory requirements around the world. We saw another example of this recently in the U. S. With the USDA's declaration of salmonella as a known adulterant in raw, breaded and stuffed chicken products, joining E.
Coli and Listeria as the other known pathogen adulterants in different food types. The USDA and other international regulatory bodies continue to focus on reducing severe illness and fatalities stemming from foodborne pathogens, and we anticipate the emergence of additional regulatory requirements in the future. Other key tailwinds in the food safety market include the increasing expectation from consumers to know what is in and not in their food, as well as the high cost associated with contaminated products reaching the shelves. Beyond the obvious tragic consequences that can result from consuming contaminated food or beverages, the cost to companies of the associated product recalls, litigation, brand damage and even facility closures can be tremendous, as evidenced recently by several unfortunate high profile outbreaks. These occurrences reinforce the value proposition of Neogen's solutions and industry expertise, which have never been more relevant than they are today.
Our commercial teams have been engaging in an increasing number of these conversations with customers, offering not only the breadth of our products and services, but also the long standing knowledge and expertise we can provide in structuring robust food safety testing programs. We expect these factors to continue to support growth in the food safety end market and a continuation of the progress we've made in expanding and in some cases, winning back market share. In Animal Safety, we continue to manage through end market conditions we believe are at or near cyclical lows, particularly in the United States where most of our business and this segment is focused. Our animal safety sales are influenced by net farm income, which after peaking in 2022 in the U. S.
Declined in 2023 and is declining again in 2024. The majority of our business in this segment goes to large distributors. And despite weaker conditions, sales of our products out of the distribution channel have continued to grow. However, our sales to our distributor partners are subject to movements in the timing of orders and inventory levels as well as any other factors or initiatives specific to individual distributors. In the Q1, some of our key distributors reduced inventory levels due to order timing from the Q4, while others did so as a result of some specific challenges they're experiencing in their particular business.
We are not seeing the indications of a destocking trend and believe the sales out of our products support an improvement in our animal safety growth rates in the coming quarters. And of course, we'll continue to monitor the channel dynamics closely. In our genomics business globally, 1st quarter revenue was down on a year over year basis, but improved from the decline we saw in the 4th quarter. We began to round trip the impact of the strategic shift towards larger production animals in the quarter and did see growth in our large animal business. This growth was offset by weakness in the companion animal side of the business, driven by lower number of new puppies and increased inflationary pressure on customers.
We are continuing to focus on driving growth in the direct to producer beef and dairy segments, while also targeting actions to right size the cost base to better align with current level of revenue. With respect to our integration progress, the ERP related challenges that we've been experiencing in our primary distribution center have been resolved and we no longer are constrained by shipping. That being said, we do see opportunity to drive improvements in the efficiency of that operation and our teams are focused on executing a number of initiatives there. On the production side, we've completed the relocation of the former 3 ms sample collection product line. While we've been in the process of ramping up our production, we haven't been able to fully keep up with end user demand, which weighed on our sample collection sales in the quarter.
We currently have all lines operational with the line of sight to reach normal production levels in the Q3. Our new Petrie Film facility is progressing well and the first of our 2 major shipments of equipment is expected to land in Lansing in January. It will take several months to uncreate everything and get it moved into the new building, but the receipt of the equipment is clearly an important milestone in that process. With the recent shipping challenges behind us, regaining market share is a top priority. The response to our initial efforts in this area have been encouraging.
We are a known and trusted partner in the industry with leading products that are globally validated and most customers are primarily focused on a demonstrated period of reliable supply. Because of this, share recapture will not happen overnight, but the progress we've made so far is in line with our expectations. Our commercial teams are executing detailed tactical plans that are driving constructive dialogue with previously impacted customers and we're looking forward to continuing to demonstrate our capabilities as a reliable, knowledgeable source of leading food safety testing solutions. I'll now turn the call over to Dave for some more insights into our results for the quarter.
Dave Namura, CFO, Neogen Corporation: Thank you, John, and welcome to everyone on the call today. Jumping into the results, our first quarter revenues $217,000,000 Core revenue, which excludes the impact of foreign currency, acquisitions and discontinued product lines declined 1% for the quarter, while foreign currency was a headwind of 3.90 basis points compared to the prior year. The Q1 is historically our seasonally lowest of the year with this year's Q1 seeing the impact of lost sales related to our shipping challenges in the second half of fiscal twenty twenty four. At the segment level, revenues in our Food Safety segment were $159,000,000 in
John Adent, CEO, Neogen Corporation: the quarter,
Dave Namura, CFO, Neogen Corporation: a decrease of 4% compared to the prior year, including core growth of 1%. The core growth was led by the indicator testing, culture media and other product category, which benefited from strong growth in our petrifilm product line as well as in food quality, nutrition and analysis and culture media. This growth was partially offset by a decline in sample collection as we fell behind demand during the process of ramping up production in our own facility. The bacterial and general sanitation product category saw modest growth in pathogens, which was offset by declines in general sanitation and microbiology. Within the natural toxins and allergens category, modest growth in allergens was offset by a decline in natural toxins.
Quarterly revenues in the animal safety segment were $58,000,000 which includes a core revenue decline of 8% compared to the prior year quarter. Within biosecurity, strong growth in rodent control products was offset by declines in insect control and cleaners and disinfectants. The Vet Instruments and Disposables product line had a slight core revenue decline, while the Animal Care and other product category had a larger core revenue decline, driven in part by supplier related product availability issues. Worldwide genomics revenue was down mid single digits on a core basis. Solid growth in beef markets was offset by the shift away from small production animals in the U.
S, the impact of which we have mostly anniversaried as of the end of Q1. From a regional perspective, core revenue growth in the Q1 was mixed. Growth was led by Latin America, which saw double digit growth with a strong performance across most key product categories. The growth was driven by continued build out of inventory across the distribution channel as well as some new business wins. Our business in Europe was roughly flat on a core basis with growth in petri film, cleaners and disinfectants, culture media and vet instruments offset by declines in sample collection, general sanitation and genomics.
Asia Pacific core revenue was down slightly on a year over year basis with growth in petri film, cleaners and disinfectants and food quality offset by declines in pathogens and general sanitation. Our U. S. And Canada regions saw the largest carryover impact from the shipment delays last year with core revenue down in the mid single digit range. Despite this impact, Petri Film and Culture Media had solid growth, which was offset by declines in most other food safety product categories.
In the Animal Safety segment, strong growth in rodent control products was offset by declines in the other major product categories. Gross margin in the Q1 was 48.4 percent representing a decrease of 2 60 basis points from 51% in the same quarter a year ago and an improvement sequentially due mostly to some reclass and one time items that impacted Q4. Adjusting for transaction and integration related costs as well as discontinued products, the year over year gross margin decline in Q1 was 90 basis points. The decline was driven primarily by lower volume and continued higher distribution costs. Adjusted EBITDA was $44,000,000 in the Q1, representing an adjusted EBITDA margin of 20.1%, a year over year decline of 2 80 basis points.
The decline in adjusted EBITDA margin was driven by lower revenue in the quarter and the decline in gross margin with additional negative impact from having the full cost to exit the various transition agreements, including some impact from higher shipping, a portion of which are reflecting in operating expenses. 1st quarter adjusted net income and adjusted earnings per share were $14,000,000 $0.07 respectively compared to $24,000,000 $0.11 in the prior year quarter. The declines in the current year Q1 were driven primarily by the lower adjusted EBITDA. We ended the quarter with gross debt of $900,000,000 67 percent of which remains at a fixed rate and a total cash position of $120,000,000 Compared to the 4th quarter, the lower Q1 cash position was driven by higher capital expenditures, a semiannual interest payment on our senior notes and the negative impact from working capital. The working capital increase was largest in payables, which was mostly timing driven and inventory where we built stock of higher running products.
Q1 represented the high point in the year for CapEx spend. We believe we are still on track with the free cash flow guidance we provided in July, but are off to a slower start than we had anticipated. Moving to our outlook for the 2025 fiscal year, we are maintaining our previously issued guidance. 1st quarter revenue developed in line with the expectations we communicated regarding lower than normal first half seasonality and we are encouraged by the performance we saw in September, which was an improvement over the 1st month of Q1. We expect our Q1 adjusted EBITDA margin to be the lowest of the year and expect margin improvement in the balance of the year to be driven by higher revenue volumes, gross margin improvement, including actions in our shipping and distribution operations and operating expense efficiency.
As I noted on capital expenditures, we anticipate our Q1 spending to be the highest level of the year followed by the Q2. We also continue to believe higher adjusted EBITDA combined with lower CapEx and the 3 ms working capital load and not repeating will result in free cash flow for this year being positive. I'll now hand the call to John for some closing thoughts.
John Adent, CEO, Neogen Corporation: Thanks, Dave. In a separate announcement this morning, we shared that Doug Jones, our Chief Operating Officer has communicated his attempt to retire in the early part of calendar 2025. Doug has had a long career across a number of industries and his experience has been a great value to Neogen, particularly his broad commercial expertise and contributions to the integration of the 3 ms transaction. In preparation for Doug's coming retirement, we have begun the search for a Chief Commercial Officer, who will report to me and have responsibilities for our global sales, marketing and communications organizations. With Doug assisting with the transition once that role is filled.
Our new Vice President of Global Operations will transition to report to Dave Niimura, our CFO, who has worked closely with the operations team here at Neogen, as well as other organizations in the past. This realignment will provide a dedicated focus on our commercial activities, while also enabling Dave to work more closely with the operations and supply chains teams to further untap improvement opportunities. Our Head of Latin America also recently announced his impending retirement after a long career with Neogen. And we have hired his replacement Enrique Carballido, who brings commercial experience from a number of multinational corporations in the diagnostic space, most recently as the Head of Latin America for Bio Rad. Finally, we recently announced the addition of a new member of our Board, Thierry Bernard, who is the current CEO of QIAGEN, a leading global provider of molecular diagnostic solutions and insights.
This addition brings the valuable insights and perspectives of an independent public company CEO to our Board, including those gained from experience in the food safety industry in prior roles. The goal of these additions and organizational realignments is to continue to bring experience and capabilities in the Neogen that puts us in the best position to execute on the significant opportunities we have in our primary end market of food safety. We are the established leader in this market and look forward to continuing to build on that position to drive sustainable long term growth. Now, I'll turn things over to the operator to begin the Q and A.
Conference Operator: Thank Your first question comes from David Westenberg with Piper Sandler. Your line is now open.
David Westenberg, Analyst, Piper Sandler: Hey guys. Thank you for taking the question. So you've had 3 ms for a little while now and there's definitely some great products that fit with your overall portfolio. How are you looking at maybe investments this year in sales and marketing, R and D, etcetera, in terms of allocation towards food safety overall now that you have this new
Conference Operator: toys
David Westenberg, Analyst, Piper Sandler: in the portfolio?
Dave Namura, CFO, Neogen Corporation: Hi, David. It's Dave. Hey, good question. I think what you've heard from us over the last year is a couple of things. A lot of commercial investment, particularly building out the international regions.
We think there continues to be a lot of opportunity. And now that we have critical mass post 3 ms acquisition, we've been putting a lot of energy there. And also, you've heard us talk about Petri Film as a platform. It's very exciting and clearly an R and D priority for us to invest in and of course in Q1 announced the new reader as well with a new feeder for higher volume processing. So I think you've heard that from us and your take is right.
It's very exciting and I think hopefully you'll continue we'll continue on that theme.
John Adent, CEO, Neogen Corporation: Yes. And look, thanks, David. We've talked a lot about capital allocation, right, and where we're going to spend our money and it's something we do and look at as a group and understand. And we see the profitability profile of those products and really a number of our other products in the food safety and that's where we're going to continue to invest. It was a thesis of the deal.
That's why we're still excited about the deal. That's why we're going to continue to put money behind it.
David Westenberg, Analyst, Piper Sandler: Yes. That definitely sounds right. And then in terms of debt and how we're thinking about debt over the course of the next 3 years, I know you don't give 3 year, 4 year out year guidance, but just in terms of the priority to pay that down, I still think that is a big capital priority for you, though I know you guys continue to think about tuck ins on a pretty ongoing basis.
Dave Namura, CFO, Neogen Corporation: Yes. Look, I think you've heard us consistently talk about capital allocation priority first funding the integration, which is vital, but then on a net basis reducing leverage. And as we do so that frees up M and A capacity, right? So I think no change there. We got to keep getting the integration work done, which we made obviously huge strides in 2024.
And as the years progress here, we think we'll be on an okay path. The guide implies around 3 times net leverage at the end of the year of the fiscal year, little higher than where we thought we'd be a few years ago at this time, but clearly manageable and I think reflective of our priorities.
David Westenberg, Analyst, Piper Sandler: Perfect. And then just one last one here. The stock out of the Petrie film, that is now well behind you. Can you talk about the customer recovery ratio, where what kind of inning you are in terms of winning all those back? Is there still a big group that you have left to win back?
Or did you get them pretty much all back over the last, say, year or so when now that you've had product on a pretty consistent basis? And that's my last one. Thank you.
John Adent, CEO, Neogen Corporation: Yes. I think thanks, David. I think there's 2 pieces of this. One is petrofoam specifically, which is what you asked about. In Japan, where we had the major issues, we've won those customers back, right?
And we're actually seeing growth in Japan. I mean, that's been a good story for us. I mean, that was I think we had multiple quarters of decline and we finally started to see that business turnaround and return to growth. And it's a really strong team. I think on the broader business where we struggled a little bit for a couple of quarters regarding our EWM system at the warehouse and hurt customers, that continues to be a focus for us to win those customers back.
That's going to take a little bit longer. We knew that we need to rebuild trust. I've had a number of discussions with customers. And like I said in my opening remarks, what they want to see is consistent supply. We've done that for a quarter and they want to see us do it again.
And so we're still on that journey. That's why we talked about for the year, how it was going to pace out in the Q1 was going to be our lowest and going to be a challenge for us. But we understood that and that we think that we're on the right track.
Brandon Vazquez, Analyst, William Blair: Thank you.
Conference Operator: Your next question comes from Brandon Vazquez with William Blair. Your line is now open.
Brandon Vazquez, Analyst, William Blair: Hey, good morning, everyone. Thanks for taking the question. Can we let's maybe start on the customer losses that you guys were just touching on. John, are you able to quantify at all what the customer is where over the past couple of quarters? I know when you guys lost customers in Japan, you were able to give us a number.
So curious if you can quantify it at all. And then maybe just spend a couple more minutes talking about when you're sitting down with these accounts, what are they saying in terms of what they want to see from you consistently? And then if you're getting a good sense that once I show them 1 or 2 quarters of supply, they will come back predominantly for most of the share losses that you kind of lost in those
Dave Namura, CFO, Neogen Corporation: Brandon, it's Dave. Just real quick, maybe quantifying a little bit. As we entered the year, you'll recall we talked about what we thought the share headwind would be is a couple points at least a couple points of growth for the year. I think what we saw in the Q1 was reasonably consistent with that. The data we look at, we think our share kind of share headwind impact was about $8,000,000 in the Q1.
That was globally the majority of that in the U. S. And I'll let John talk to kind of the customer interaction and how this is coming along.
John Adent, CEO, Neogen Corporation: Yes. Thanks, Dave. So, Brian, a lot of discussion with the customers I have is first they want to express to me their frustration, right? And so and I tell them there's no one more frustrated than me in the way that we were not able to meet their needs. Pretty much right after that, we've talked about what are the things that we've done and the improvements we've seen.
So we share that with them. I'll give you a good example. One is regarding MDS. We've already have efficiency improvements in that line in 6 months being under our efficiency improvements in that line in 6 months being under our roof than when it was in 3 ms. And I think that's what gives me a lot of excitement is we spent a lot of time and energy in the last 2 years of working on integration to carve the business out and bring it into ours.
And now what we're starting significant teams in the engine are starting to refocus that energy and time from integration efforts to efficiency and growth efforts, which is what I'm really excited to see the team do. I can show those points to customers. I show them the petri film, how we've increased the availability of the product line. I can show them the efficiency in MDS. I can show them the progress we're making.
And those are the things that allow us to continue to have discussions. The majority of the time, it's I listen, we have a discussion and then we re sign the contract. Those are the ways that those a lot of those discussions have been progressing.
Brandon Vazquez, Analyst, William Blair: Okay, great. And Dave, maybe back to you now with 1 quarter under the belt and maybe 1 month under the belt into the next quarter and knowing the conversations that you're having with customers at this point, just curious if there's any you have a range out there for guidance for the year. Curious if conversations are leaning you towards one way or another on the range or even if you could just talk about what gets you to the high and the low end of those ranges through the rest of the year?
Dave Namura, CFO, Neogen Corporation: Yes. Thanks, Brandon. I think here just with the Q1 behind us and yes, a view of September, which for 1st month of the quarter, we saw some improvement for the 1st month of Q2 versus Q1. I don't think it informs that we would narrow the range per se. There's still uncertainty around the timing of pace of share recovery.
There's uncertainty more broadly in our end markets. And so I think the things we talked about when we set the guide kind of still exist kind of 1 quarter in here. And most importantly, when we talked about the guide, we talked about this year being a little more second half weighted. So historically, maybe we'd be 48% in the first half, 52% in the second. We see that shifting to a little more second half weighted, which I think creates the need for the volume ramp, makes it a little bit bigger.
So I think we still remain where we are. And to your point, as the year develops here, hopefully, we can help color it a little better.
Brandon Vazquez, Analyst, William Blair: Okay. And maybe I'll throw 2 quick ones out there. John, is there any feedback in the early days of the high volume petri film feeder that you could share with us at this point? And then Dave, just for you, just so that we can kind of talk about it on the broad call, any impacts that we should keep in mind from the ongoing the past 2 hurricanes in Southeast? Thanks guys.
John Adent, CEO, Neogen Corporation: Sure, you bet. I only have one anecdotal story for you, Brandon, where we had a customer that was testing it and we said, okay, it's time to take it back. And he said, there's no way you're taking it back. So that's my one anecdotal story. I think if I could add something else, this quarter has been challenging for us as an industry.
And you think about if you think about relevancy of our business, we've had 2 major outbreaks with major companies that have had devastating impact on their consumers. And it just goes to show what we do and why we're important. And one of the things I'll tell you is we had a meeting where one of the things we did for our research, our tech service teams was like we put up the number of people that were affected by that died to foodborne illness in the United States. And our job is to make sure that doesn't happen. And while we continue to see these things go up, the issue is you have to continue to look forward.
A lot of these companies didn't have a problem for 100 years until they had a problem. And I think that's why it's important when you look at what we do with our environmental monitoring programs, our risk assessments to help these customers continue to look forward and not backwards and rest on kind of where they are because the world's constantly changing and whether to your point, whether it's environmental change, where all of a sudden you've got plants that it wasn't never flooded before, it wasn't as humid, now it's more humid. Those are all risk assessments that we have to update, help our customers update to continue to protect the food supply. So I'll let Dave talk specifically about the hurricanes, but I just wanted to make sure that 2 major things happened in this quarter we need to keep an eye on.
Dave Namura, CFO, Neogen Corporation: Yes, Brandon, and I don't have a quantification of the recent storms in the South. Obviously, the results of Milton here are pretty fresh. And so it's something we're keeping an eye on the logistical impacts and other things at this stage, but I don't have a quantification at this time.
Conference Operator: Your next question comes from Thomas Debuchry with Nephron Research. Your line is now open.
Thomas Debuchry, Analyst, Nephron Research: Hi, guys. Can you hear me all right?
John Adent, CEO, Neogen Corporation: Yes. Tom DeBorsy, I can hear you.
Thomas Debuchry, Analyst, Nephron Research: Okay, great. So my question is, I guess, around the Chief Commercial Officer position that you're creating. I know it's kind of being carved out of an existing role, but and I guess kind of it seems like it ties together at an opportunistic time where maybe both your end markets have been cyclically weaker and now we're kind of going back to a period of strength and revenue generation opportunities, you may be meeting with more customers that are more receptive to offerings. But so how are you thinking about both the C suite role, but then also what else Neogen could do in terms of, I guess, additional revenue generation and new customer acquisition?
John Adent, CEO, Neogen Corporation: Yes, great. No, thanks, Tom. A couple of things with that. I think that's why we're splitting it to a Chief Commercial Officer role and not a Chief Operating Officer role because we see the opportunity to continue to focus. And the reason we're able to do that is because Doug did such a fantastic job when he was here building out his team.
And we have a really, really strong Vice President of Operations that we are very happy to have on board. Jim has been with us over a year, right around a year and is making tremendous impact. And so it gives us great confidence in him running the operational side and really then hiring someone that's going to focus fully on demand generation. And for those of you, I've worked with Doug for over a decade. He's done a great job.
We're really happy that he's got the opportunity to retire and do some other things that he wanted to do. And I'm even happier that he built such a strong team that's allowing us to make these types of organizational moves in a way that is planned and allows us to meet the needs of the business going forward.
Thomas Debuchry, Analyst, Nephron Research: Got it. And just I guess as a follow-up to the cost side, kind of I guess the ongoing portfolio review, is it thinking about part of the 3 ms business you acquired? It seems like there were some areas where you might have some overlapping products and whether there's some, I guess, consolidation opportunities or maybe they serve different customers, but then also how you're looking at potential lower margin products and whether exiting those products or selling sub products maybe a good return on capital?
John Adent, CEO, Neogen Corporation: Yes. No, I think that's right, Tom. And we've done some of that already. I mean, it's not something that we went out and publicized, but we paired some of the we've already worked with customers in a new bar to pair some lines that we've got from 3 ms. We have but we also have to look at that with our own portfolio, right?
And that's something that we told you we've been working on the last year. And while we don't have anything to announce today, it's something that we continue to focus on and continue to evaluate because we're looking at where we get the greatest return for our capital. So capital allocation right now is really important for us and making sure that we are investing in the areas for the greatest return is what we're laser focused on right now.
Thomas Debuchry, Analyst, Nephron Research: And then just maybe the last question, geographically, China has continued to be a focus on the animal health, animal safety side, whether it's with African swine fever or other issues that obviously have been happening over the last few years. Just how do you view kind of the importance of that market for NeoGen's growth? That will do it for me.
John Adent, CEO, Neogen Corporation: Yes. I think, Tom, looking at the Asia Pacific region in whole is more important for us. It is a tremendous growth opportunity for us in a lot of different markets. We've got a really strong team in Japan. We've got a strong team in Korea.
We're building out a strong team in the Philippines. We've got a strong team in Thailand. We've got a strong team in China. So we're not reliant on just China for our growth. And as you know, China has been challenging, which has been good because we have such a broad mix and such a broad sales mix across that region.
So we're really focusing on Asia Pacific. And as Dave talked about earlier, really all of our international regions, that's where we're placing our money to expand those teams internationally because we have such low market share. And we've seen really good opportunities for that. You continue to see we've seen Japan, which is our largest market single country outside the U. S, turn the corner and start to grow again, which we're excited about.
We've continued to see significant growth in LatAm. We continue to see growth in Europe. And if those markets continue to outgrow North America, we're going to continue to invest in those markets.
Conference Operator: Great. Thank you. That's it for me. Appreciate it. There are no further questions at this time.
I will now turn the call over to John for closing remarks.
John Adent, CEO, Neogen Corporation: Again, thank you very much for joining. And like we talked about, as we saw this quarter, it shows the relevancy of Neogen to protect the world's food supply because you've we saw major companies have very significant issues that have affected a lot of consumers in the U. S. Specifically. So, we're continuing to show that we are the leader in the space.
We continue to develop new and innovative solutions to help those customers understand what the risks are and how to mitigate those within their facilities. So, thank you very much and we will see you again at the next call.
Conference Operator: Ladies and gentlemen, this concludes your conference call for today. We thank you for participating and ask that you please disconnect your lines.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.